What were Syncom Formulations (India) Ltd's latest quarterly results?
Syncom Formulations (India) Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +38.9%
- Revenue Growth YoY: -9.4%
- Operating Margin: 16.0%
Syncom Formulations (India) Ltd: Stock Analysis & Fundamentals
Updated this weekSyncom Formulations (India) Ltd (Pharma - Others) — fundamental analysis, earnings data, and key metrics. PE: 17.1. ROE: 20.2%. This stock is not currently in the Nifty 500 momentum outperformers list.
Syncom Formulations (India) Ltd Key Facts
What's Happening
🏦Virtually debt-free company
Key Numbers
Current Price
₹14
Market Cap
1.3K Cr
Valuation
N/AOther Top Pharma - Others Stocks Beating Nifty 500
Frequently Asked Questions: Syncom Formulations (India) Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Syncom Formulations (India) Ltd's current PE ratio?
Syncom Formulations (India) Ltd's current PE ratio is 17.1x.
- Current PE: 17.1x
- Market Cap: 1.3K Cr
What is Syncom Formulations (India) Ltd's price-to-book ratio?
Syncom Formulations (India) Ltd's price-to-book ratio is 3.1x.
- Price-to-Book (P/B): 3.1x
- Book Value per Share: ₹4
- Current Price: ₹14
Is Syncom Formulations (India) Ltd a fundamentally strong company?
Syncom Formulations (India) Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 27.0%
Is Syncom Formulations (India) Ltd debt free?
Syncom Formulations (India) Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹1 Cr
What is Syncom Formulations (India) Ltd's return on equity (ROE) and ROCE?
Syncom Formulations (India) Ltd's return ratios over recent years
- FY2024: ROCE 11.0%
- FY2025: ROCE 19.0%
- FY2026: ROCE 27.0%
Is Syncom Formulations (India) Ltd's cash flow positive?
Syncom Formulations (India) Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹58 Cr
- Free Cash Flow (FCF): ₹7 Cr
- CFO/PAT Ratio: 76% (adequate)
What is Syncom Formulations (India) Ltd's dividend yield?
Syncom Formulations (India) Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹14
Who holds Syncom Formulations (India) Ltd shares — promoters, FII, DII?
Syncom Formulations (India) Ltd's shareholding pattern (Mar 2026)
- Promoters: 50.6%
- FII (Foreign): 0.2%
- Public: 49.2%
Is promoter holding increasing or decreasing in Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 50.6% (Mar 2026)
- Previous Quarter: 50.6% (Dec 2025)
- Change: 0.00% (stable)
Is Syncom Formulations (India) Ltd a new momentum entry or an established outperformer?
Syncom Formulations (India) Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Syncom Formulations (India) Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Syncom Formulations (India) Ltd may be worth studying
- Cash flow is positive — CFO ₹58 Cr
What is the investment thesis for Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd investment thesis summary:
What is the future outlook for Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.